Hiltonol

Oncovir is a clinical-stage biopharmaceutical company focused on developing Hiltonol (poly-ICLC), a synthetic double-stranded RNA complex that acts as a potent immune modulator. Hiltonol functions as a Toll-like receptor 3 (TLR3) agonist and inducer of interferon, designed to stimulate the innate and adaptive immune systems against cancer and infectious diseases. The company's primary focus is on oncology, particularly glioblastoma and other solid tumors, where Hiltonol is used both as a standalone therapy and as an adjuvant for vaccines and other immunotherapies. Oncovir collaborates extensively with academic and clinical institutions to advance its pipeline through various clinical trials.